Home › Employers › Candel Therapeutics, Inc.
Candel Therapeutics, Inc.: H-1B salaries and sponsorship
Candel Therapeutics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $75,442.
Does Candel Therapeutics, Inc. sponsor H-1B visas?
Candel Therapeutics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Jun 17, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Green card (PERM) applications at Candel Therapeutics, Inc.: 3 →
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Regulatory Affairs Associate | 1 | — |
| Clinical Research Associate | 1 | $73,674 |
| Clinical Trial Data Associate | 1 | $77,210 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2024 | 3 | $75,442 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Clinical Trial Data Associate | $77,210 Level I | Needham, MA | Jun 17, 2024 | Oct 1, 2024 | Certified |
| Regulatory Affairs Associate | $75,920 part-time · Level II | Mason, OH | Nov 29, 2023 | Dec 5, 2023 | Certified |
| Clinical Research Associate | $73,674–$90,000 Level II | Needham, MA | Sep 29, 2023 | Oct 16, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).